ProCE Banner Activity

IO Combinations in First-line Advanced HCC: Current Evidence and Ongoing Trials

Slideset Download
Download this slideset from Ghassan K. Abou-Alfa, MD, MBA, to see the latest data on first-line immunotherapy treatment options for patients with advanced hepatocellular carcinoma.

Released: October 14, 2020

Expiration: October 13, 2021

No longer available for credit.

Share

Faculty

Ghassan K. Abou-Alfa

Ghassan K. Abou-Alfa, MD

Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
Assistant Professor
Weill Medical College at Cornell University
New York, New York

Ghassan K. Abou-Alfa

Ghassan K. Abou-Alfa, MD, MBA

Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Program Director Disclosure

Program Director

Ghassan K. Abou-Alfa, MD

Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
Assistant Professor
Weill Medical College at Cornell University
New York, New York

Ghassan K. Abou-Alfa, MD, MBA

Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York